Katerina Angelopoulou

Katerina Angelopoulou

Auto-generated profile, based on publicly available information

Katerina Angelopoulou

Laboratory of Biochemistry and Toxicology, School of Veterinary Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2006 in Virus Research
Verified
Journal Article
Closed access
KAK. Angelopoulou
K. Angelopoulou
GBGeorgia Brellou
Georgia Brellou
TGT. Greenland
T. Greenland
IVI. Vlemmas
I. Vlemmas

1 March 2008 in The Veterinary Journal
Verified
Journal Article
Closed access
KAK. Angelopoulou
K. Angelopoulou
TPT. Poutahidis
T. Poutahidis
GBGeorgia Brellou
Georgia Brellou
TGT. Greenland
T. Greenland
IVI. Vlemmas
I. Vlemmas

1 June 2020 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
HAHara Afaloniati
Hara Afaloniati
KAKaterina Angelopoulou
Katerina Angelopoulou
AGAlexander Giakoustidis
Alexander Giakoustidis
ACAlexandros Chardas
Alexandros Chardas
Athanasios PseftogasAthanasios Pseftogas
Athanasios Pseftogas
Dimitris E. GiakoustidisDimitris E. Giakoustidis
Dimitris E. Giakoustidis
Background: Hepatocellular carcinoma (HCC) is a frequently diagnosed cancer and a leading cause of cancer-related death worldwide. Its rapid progression, combined with the limited treatment options at late stages, imposes the need for early detection and aggressive intervention. Based on the knowledge that hepatocarcinogenesis is significantly influenced by histone acetylation, we directed our search for novel HCC therapeutics among histone deacetylation inhibitors (HDACi). The aim of the present study was to investigate the effect of HDAC1/2 inhibitor Romidepsin in the well-established mouse model of diethylnitrosamine (DEN)-induced HCC. Materials and Methods: C56BL/6 mice were treated with Romidepsin at the critical point of 10 months after DEN challenge and their livers were examined 2 months later using histopathology and morphometry. Protein levels were assessed in serum using ELISA and in liver tissues using Western blot and immunohistochemistry (in-situ detection). Gene expression was quantified using real-time PCR. Results: Romidepsin suppressed cancer progression. This effect was associated with decreased proliferation and increased apoptosis of cancer cells. The cell cycle regulator CK2a, the anti-inflammatory molecule PPAR-γ, and the tumor suppressors PTEN and CYLD were upregulated in treated HCC. By contrast, the expression of PI3K, NF-κB p65 and c-Jun was reduced. In line with this result, the levels of two major apoptosis regulators, ie, BAD and the multifunctional protein c-Met, were lower in the blood serum of treated mice compared to the untreated mice with HCC. Conclusion: These findings suggest that Romidepsin, a drug currently used in the treatment of lymphoma, could also be considered in the management of early-stage HCC.

10 September 2015 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
GKGeorge S. Karagiannis
George S. Karagiannis
HAHara Afaloniati
Hara Afaloniati
EKElisavet Karamanavi
Elisavet Karamanavi
TPTheofilos Poutahidis
Theofilos Poutahidis
KAKaterina Angelopoulou
Katerina Angelopoulou

22 November 2019 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
HAHara Afaloniati
Hara Afaloniati
GKGeorge S. Karagiannis
George S. Karagiannis
EKEmmanouel Karavanis
Emmanouel Karavanis
TPTheophano A. Psarra
Theophano A. Psarra
AKAnastasios Karampatzakis-Kouritas
Anastasios Karampatzakis-Kouritas
KAKaterina Angelopoulou
Katerina Angelopoulou

1 December 2017 in Experimental Cell Research
Verified
Journal Article
Closed access
HAHara Afaloniati
Hara Afaloniati
GKGeorge S. Karagiannis
George S. Karagiannis
ACAlexandros Chardas
Alexandros Chardas
TPTheofilos Poutahidis
Theofilos Poutahidis
KAKaterina Angelopoulou
Katerina Angelopoulou